Author:
Chuang-Stein Christy,Kirby Simon
Publisher
Springer International Publishing
Reference18 articles.
1. Antonijevic, Z., Kimber, M., Manner, D., et al. (2013). Optimizing drug development programs: Type 2 diabetes case study. Therapeutic Innovation & Regulatory Science, 47(3), 363–374.
2. Bolognese, J., Bhattacharyya, J., Assaid, C., & Patel, N. (2017). Methodological extensions of Phase 2 trial designs based on program-level considerations: Further development of a case study in neuropathic pain. Therapeutic Innovation & Regulatory Science, 51, 100–110.
3. Burman, C. F., Grieve, A., & Senn, S. (2007). Decision analysis in drug development. In A. Dmitrienko, C. Chuang-Stein, & R. D’Agostino (Eds.), Pharmaceutical Statistics Using SAS®: A Practical Guide (pp. 385–428). SAS Institute.
4. Chen, C., & Beckman, R. A. (2009). Optimal cost-effective designs of phase II proof of concept trials and associated go-no go decisions. Journal of Biopharmaceutical Statistics, 19(3), 424–436.
5. Chen, C., & Beckman, R. A. (2014). Maximizing return on socioeconomic investment in Phase 2 proof-of-concept trials. Clinical Cancer Research, 20(7), 1730–1734.